Page 2429 - Williams Hematology ( PDFDrive )

2400 Index Index 2401

Anti-CD52 monoclonal antibody. Anti-IL-5 monoclonal antibody, 959, 1470 immunomodulatory drugs, 333–335, 333f
See Alemtuzumab Anti-IL-6 monoclonal antibody. See lenalidomide. See Lenalidomide
Anticoagulants/anticoagulation. Siltuximab pomalidomide. See Pomalidomide
See Antithrombotic therapy Anti-IL-6 receptor monoclonal antibody. thalidomide. See Thalidomide
Anticodon, 147 See Tocilizumab molecularly targeted small molecules,
Anticonvulsants, megaloblastic anemia and, Anti-inhibitor coagulant complex (AICC), 338–343, 339t, 340f
606t 2185 ibrutinib. See Ibrutinib
Anti-D alloimmunization, 850, 1253–1254 Anti-integrin α β , 1995 janus kinase inhibitors, 341–342
IIb 3
Antidepressants, platelet function and, 2079 Antilymphocyte serum (ALG), 522 proteasome inhibitors, 342–343. See also
Antierythrocyte antibodies. See Erythrocyte Antineoplastic drugs/chemotherapy, Bortezomib; Carfilzomib
antibodies 315–346. See also specific drugs tyrosine kinase inhibitors. See Tyrosine
Antifibrinolytic therapy, 2317–2318 acute myelogenous leukemia and, 1374, kinase inhibitors
agents 1374t monoclonal antibodies. See Monoclonal
aprotinin, 2318 agents of diverse mechanisms, 331–333 antibodies
ε-aminocaproic acid (EACA). L-asparaginase. See L-Asparaginase platelet function and, 2079
See ε-aminocaproic acid (EACA) bleomycin. See Bleomycin resistance to, 318, 319t
tranexamic acid. See Tranexamic acid alkylating drugs. See Alkylating drugs topoisomerase inhibitors, 326–329
for bleeding not response to platelet antitubulins, 325–326 anthracycline antibiotics, 327–328. See
transfusion, 2385 taxanes, 326 also Daunorubicin; Doxorubicin;
for combined deficiency of factors V and vinca alkaloids. See Vinblastine; Epirubicin; Idarubicin;
VIII, 2140 Vincristine Mitoxantrone
for disseminated intravascular coagulation, aplastic anemia and, 517t, 519 camptothecins, 326–327
2214 basic principles, 316–318 epipodophyllotoxins, 328–329. See also
for hemophilia A, 2123 cell cycle-specific agents, 318–325 Etoposide; Teniposide
indications, 2317t 5-azacytidine. See 5-Azacytidine for transplantation preparation, 360–361
platelet function and, 2078 cladribine. See Cladribine Antineutrophil cytoplasmic antibodies
Antigen collection, 2329 clofarabine. See Clofarabine (ANCAs), 959–960, 2107
Antigenicity, 2336 cyclin-dependent kinase inhibitors, 218 Antioxidant protein 2 (AOP2), 790
Antigen-presenting cells. See Dendritic cells cytarabine. See Cytarabine (ara-C) Antioxidants, porphyria cutanea tarda and,
(DCs) fludarabine phosphate. See Fludarabine 907
Antigens phosphate Anti-PF4–heparin antibodies, 2029–2030,
cross-presentation, 308 gemcitabine. See Gemcitabine 2030t. See also Heparin-induced
for cytomegalovirus-specific T cells, hydroxyurea. See Hydroxyurea thrombocytopenia (HIT)
409–410 methotrexate. See Methotrexate Antiphosphatidyl serine antibody assay, 2242
defined, 2336 nelarabine, 323f, 325, 1518 Antiphospholipid antibodies, 1995,
discovery of, for cancer vaccine therapy, pentostatin. See Pentostatin 2233–2235, 2236f, 2237
421, 422t (deoxycoformycin) Antiphospholipid syndrome (APS),
erythrocyte. See Erythrocyte antigens purine analogues. See Purine analogues 2233–2245
for leukemia-specific T cells, 413 cell kinetics and, 317 antiannexin A2 antibodies in, 1976
leukocyte. See Human leukocyte antigen combination chemotherapy, 317 catastrophic, 2239, 2245
(HLA) differentiating agents, 335–336 in children, 2241
for melanoma-specific T cells, 412 arsenic trioxide. See Arsenic trioxide clinical features, 2100, 2101f, 2234t,
minor histocompatibility, 413–414 retinoids, 335. See also ATRA 2238–2241, 2238f, 2238t, 2240t
neutrophil. See Human neutrophil antigens (all-trans-retinoic acid) definition and history, 2233–2234
(HNAs) dose modification for renal or hepatic differential diagnosis, 2244
platelet. See Human platelet antigens dysfunction, 316, 316t etiology, 2234
(HPAs) epigenetic agents, 336–338 immune thrombocytopenia in, 2008
self-, 2343 demethylating agents, 336. See also laboratory features, 2234t, 2241–2244,
tumor, categories of, 412t 5-Azacytidine; Decitabine 2241t
uptake and processing in dendritic cells, future targets, 337–338, 337f pathogenesis, 2234–2237, 2235f, 2235t,
308–309 histone deacetylase inhibitors, 240, 2236f, 2237f
Antihemophilic factor. See Factor VIII 336–337. See also Romidepsin; in pregnancy, 2239, 2244, 2245
Antihistamines Vorinostat therapy, course, and prognosis, 2234–2245
for allergic transfusion reactions, 2375 high-dose regimens with stem cell support, Antiplatelet antibodies, 2084–2085
for mastocytosis, 976 331, 331t, 332t Antiplatelet drugs, 394t, 403–406, 404t. See
platelet function and, 2079 history, 315–316 also specific drugs

Kaushansky_index_p2393-2506.indd 2400 9/21/15 3:21 PM